The patient with refractory gastroesophageal reflux disease

Diseases of the Esophagus

Volumn 19, Issue 6, 2006, Pages 443-447

  Richter, Joel E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALLERGEN; ASCORBIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; DOXYCYCLINE; ESOMEPRAZOLE; FERROUS SULFATE; FLUTICASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; MONTELUKAST; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM CHLORIDE; PREDNISONE; PROTON PUMP INHIBITOR; QUINIDINE; RANITIDINE; STEROID; SUCRALFATE; TACROLIMUS; TETRACYCLINE;

BOUGIE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERANCE; EOSINOPHILIC ESOPHAGITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS ACHALASIA; ESOPHAGUS BIOPSY; ESOPHAGUS DILATATION; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; GENETIC VARIABILITY; HEARTBURN; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LICHEN PLANUS; MUCOUS MEMBRANE PEMPHIGOID; PEMPHIGUS VULGARIS; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN DISEASE; STOMACH PH; SYMPTOMATOLOGY; THRUSH; TREATMENT RESPONSE; ZOLLINGER ELLISON SYNDROME;

ALGORITHMS; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; EOSINOPHILIA; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; SKIN DISEASES;

EID: 33750466191     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00619.x     Document Type: Review

References (30)

1. Bardham K D. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9: 15-25.
2. Barrison A F, Jarbe L A, Weinberg M D et al. Patterns of proton pump inhibitors in clinical practice. Am J Med 2001; 111: 469-73.
3. Fass R, Sontag S J, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: A double-blind randomized trial. Clin Gastroenterol Hepatol 2006; 4: 50-6.
4. Martinez S D, Malagon I B, Garewal H S et al. Non-erosive reflux disease (NERD), acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.
5. Charbel S, Khandwala F, Vaezi M F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 283-9.
6. Kikendall J W. Pill-induced esophageal injury. In: Castell D O, Richter J E, eds. The Esophagus, 4th edn. Philadelphia: Lippincott Williams & Wilkins 2004: 572-84.
7. Abid S, Mumtaz K, Jafri W et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37: 470-4.
8. Wise J L, Murray J A. Esophageal manifestations of dermatologic disease. Current Gastroenterol Rep 2002; 4: 205-12.
9. Keate R F, Williams J W, Connolly S M. Lichen planus: Report of three patients treated with oral tacrolimus or intraesophageal corticosteroid injection or both. Dis Esophagus 2003; 16: 47-53.
10. Miller L S, Vinayek R, Frucht H et al. Reflux esophagitis in patients with the Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6.
11. Hirschowitz B I, Simmons J L, Johnson L F, Mohnen J. Risk factors for esophagitis in extreme acid hypersecretion with and without Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2004; 2: 220-9.
12. Furuta T, Shirai N, Watanabe F et al. Effect of the cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Therapeutics 2002; 72: 453-60.
13. Schwab M, Klotz U, Hofmann U et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78: 627-34.
14. Fox V L, Nurko S, Furuta G T. Eosinophilic esophagitis: It's not just kids stuff. GI Endoscopy 2002; 56: 260-70.
15. Mishra A, Hogan S P, Brandt E B et al. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001; 107: 83-90.
16. Morrow J B, Vargo J J, Goldblum J R, Richter J E. The ringed esophagus: histological features of GERD. Am J Gastroenterol 2001; 96: 984-9.
17. Teitelbaum J, Fox V, Twarog F et al. Eosinophilic esophagitis in children: Immunopathological analysis and response to fluticasone propionate. Gastroenterol 2002; 122: 1216-25.
18. Straumann A, Spichtin H P, Grize L et al. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterol 2003; 125: 1660-9.
19. Peghini P L, Katz P O, Castell D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
20. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
21. 2-receptor antagonists. Dig Dis Sci 1990; 35: 976-83.
22. Sifrim D, Holloway R, Silny J et al. Acid, non-acid, and gas reflux in patients with gastro-esophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001; 120: 1588-98.
23. Vaezi M F, Lacamera R G, Richter J E. Validation studies of Bilitec 2000: An ambulatory duodenogastric reflux monitoring system. Am J Physiol 1994; 267: G1050-75.
24. Koek G H, Tack J, Sifrim D et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96: 2033-40.
25. Marshall R E, Anggiansah A, Owen W A, Owen W J. The relationship between acid and bile reflux and symptoms in ortho-oesophageal reflux disease. Gut 1997; 40: 182-7.
26. Shay S, Tutuian R, Sifrim D et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: A multi-center report of normal values in 60 healthy volunteers. Am J Gastroenterol 2004; 99: 1037-43.
27. Koek G H, Sifrim D, Lerut T et al. Effect of the GABA B agonist baclofen in patients with symptoms and DGE reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
28. Pandolfino J E, Richter J E, Ours T M et al. Ambulatory esophageal pH monitoring using a wireless technique. Am J Gastroenterol 2003; 98: 545-50.
29. Fletcher J, Wirz A, Henry E, McColl K E L. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of stat segment reflux. Gut 2004; 53: 168-73.
30. Fass R, Tougas G. Functional heartburn: The stimulus, the pain and the brain. Gut 2002; 51: 885-92.